Imunon presents new translational data for IMNN-001 at SITC 2026

Imunon announced new translational data from its randomized Phase 2 OVATION 2 trial of IMNN-001, a DNA-based immunotherapy for newly diagnosed advanced ovarian cancer, presented at SITC 2026. The data show adding IMNN-001 to standard-of-care chemotherapy increases anti-tumor T-cell activity.

Detected & updated continuously · Source: Nebula